InvestorsHub Logo
Followers 827
Posts 119484
Boards Moderated 15
Alias Born 09/05/2002

Re: brooklyn137 post# 107

Tuesday, 09/07/2010 10:25:58 PM

Tuesday, September 07, 2010 10:25:58 PM

Post# of 125
Your milestone figure includes $287M of clinical/regulatory milestones pertaining to non-HCV indications (presumably HBV) and $285M of sales-based milestones. It’s unlikely, IMO, that BMY would ever have had to pay ZGEN all of the latter or any of the former.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”